What is GIST, and what does Qinlock (ripretinib) target?
GIST (gastrointestinal stromal tumor) is a cancer that typically grows in the stomach or small intestine and is driven by certain genetic changes. Qinlock (ripretinib) is a targeted cancer therapy designed to inhibit the tumor-driving proteins in GIST, including KIT and PDGFRA (the kinases commonly altered in GIST). Qinlock is used in people whose GIST has progressed after earlier treatments. [1][2]
How does Qinlock work once it’s in the body?
Qinlock is a kinase inhibitor. By blocking KIT and PDGFRA signaling, it helps stop the cancer cells from using those pathways to grow and survive. This matters because many GISTs depend on continuous KIT/PDGFRA activity, and later-line therapies are aimed at overcoming resistance that can develop to earlier drugs. [1][2]
How does this differ from earlier GIST drugs?
Earlier GIST treatments (such as imatinib and sunitinib, depending on the patient’s prior therapy and tumor genetics) also target KIT/PDGFRA, but resistance can arise through changes in the kinase domain. Qinlock is built to inhibit switch-control and activation-loop regions of KIT/PDGFRA, which is intended to help in tumors that have become resistant to earlier therapies. [1][2]
When is Qinlock used in GIST treatment?
Qinlock is used after a person’s GIST has progressed on prior therapy (i.e., it is a later-line option). The exact timing in a treatment sequence depends on what drugs were used before and the individual’s tumor characteristics. [1][2]
What patients usually look for: response and disease control
People taking Qinlock are generally looking for tumor shrinkage or, at minimum, disease control (slowing growth) after resistance to prior treatments. Clinical use is guided by how the tumor responds on imaging and by tolerability in practice. [1][2]
---
Sources
[1] DrugPatentWatch.com – Qinlock (ripretinib) overview: https://www.drugpatentwatch.com/p/drug/qinlock
[2] DrugPatentWatch.com – Ripretinib / Qinlock patent and related context: https://www.drugpatentwatch.com/p/drug/ripretinib